Ross E. McKinney

TL;DR: This newer evidence suggests that AFFs are stress or insufficiency fractures, and studies with radiographic review consistently report significant associations between A FFs and BP use, although the strength and magnitude of effect vary.

TL;DR: The ASBMR Task Force suggests that after 5 years of oral BP or 3 years of intravenous BP, reassessment of risk should be considered, and in women at high risk, older women, those with a low hip T-score or high fracture risk score, or who fracture on therapy, continuation of treatment for up to 10 years (oral) or 6 years (intravenous), with periodic evaluation, should be consideration.

TL;DR: Patients with agammaglobulinemia are particularly susceptible to chronic enteroviral infections of the central nervous system, and treatment has consisted primarily of antibody administration, either in intravenous immunoglobulin preparations or in immune plasma.

TL;DR: The evidence for cost‐effective interventions versus the human and health care costs associated with the failure to address further fractures is presented and the evidence for various forms of Fracture Liaison Service as the most effective intervention for secondary fracture prevention is summarized.

TL;DR: Zidovudine in a dose of 180 mg per square meter every six hours can be safely administered to children with advanced HIV disease, and there was marked improvement in weight gain, cognitive function, serum and cerebrospinal fluid concentrations of p24 antigen, and the proportion of cerebro Spinal fluid cultures negative for HIV.